An Eye Drop Aims for the Retina. Delivery Still Needs Proof.
Foventa is developing FOV407 as an eye drop for diabetic retinal disease. Early clinical observations and a proposed trans-scleral route do not yet establish retinal drug concentration or clinical efficacy.
The destination influenced molecule selection
In September 2026, Exonate renamed itself Foventa Therapeutics and said it would focus on FOV407, an investigational eye drop for non-proliferative diabetic retinopathy. The company says it evaluated the candidate in earlier phase Ib/IIa studies and is preparing a phase IIb study. It has reported an early observation of reduced vascular leakage, but the announcement does not establish a definitive clinical benefit or show that phase IIb dosing has begun. [1]
Foventa proposes that a dose placed on the eye’s surface can cross the sclera and move toward tissues at the back of the eye. That is its development hypothesis, not a published map of drug concentrations across a patient’s ocular tissues. Historical University of Nottingham material describes porcine-eye permeability experiments and subsequent optimization of potency, permeability, solubility and retinal distribution. The evidence comes from early research; it is not a human retinal pharmacokinetic result for FOV407. [2, 3]
What the next study must separate
This approach differs from simply putting an active molecule into a conventional eye-drop bottle. A candidate has to be pharmacologically suitable and able to reach the intended tissue. Company statements about a potential trans-scleral route, earlier exploratory observations and a planned later trial sit at different evidence levels. Even a systemic blood measurement after dosing would not directly measure drug at the retina.
The next questions concern ocular exposure, safety, retinal outcomes and whether the treatment changes disease progression in a controlled study. Current care for diabetic retinopathy also includes monitoring and management of blood glucose, blood pressure and lipids; this investigational drop is not a substitute for medical advice or established care. N1 Life has no stated role in Foventa’s program. [4]